

Giuseppe Gritti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5645064/publications.pdf>

Version: 2024-02-01

57
papers

1,687
citations

394421

19
h-index

315739

38
g-index

63
all docs

63
docs citations

63
times ranked

3180
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the T cell receptor β -chain constant region for immunotherapy of T cell malignancies. <i>Nature Medicine</i> , 2017, 23, 1416-1423.	30.7	196
2	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , 2015, 100, 77-86.	3.5	147
3	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	1.6	120
4	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , 2020, 225, 152001.	1.9	120
5	Sleeping Beauty“engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	8.2	102
6	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. <i>Nature Immunology</i> , 2021, 22, 19-24.	14.5	101
7	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	1.4	69
8	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	1.6	66
9	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	7.2	57
10	The lymphocyte to monocyte ratio improves the IPI“risk definition of diffuse large B“cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 1062-1067.	4.1	54
11	Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. <i>Leukemia</i> , 2008, 22, 646-649.	7.2	47
12	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	5.2	47
13	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> , 2021, 35, 2710-2714.	7.2	42
14	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	2.4	29
15	Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. <i>Blood</i> , 2020, 136, 2628-2637.	1.4	29
16	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 25-37.	1.4	29
17	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020, 4, 819-829.	5.2	28
18	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin“ lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	1.8	21

#	ARTICLE	IF	CITATIONS
19	Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. <i>American Journal of Hematology</i> , 2011, 86, 650-656.	4.1	20
20	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2871-2871.	1.4	20
21	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-455.	1.6	18
22	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival. <i>PLoS ONE</i> , 2014, 9, e106745.	2.5	18
23	An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 481-489.	2.5	17
24	Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 936-937.	4.1	14
25	Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2767-2770.	1.3	14
26	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	7.0	13
27	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. <i>Blood</i> , 2020, 136, 45-47.	1.4	13
28	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	1.7	13
29	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 424-429.	1.3	11
30	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	3.5	11
31	IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017010.	1.3	9
32	Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. <i>Respiratory Medicine</i> , 2021, 185, 106477.	2.9	9
33	Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas. <i>PLoS ONE</i> , 2015, 10, e0121822.	2.5	9
34	Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. <i>Oncotarget</i> , 2018, 9, 9766-9775.	1.8	9
35	Chimeric antigen receptor T cells for gamma-delta T cell malignancies. <i>Leukemia</i> , 2022, 36, 577-579.	7.2	8
36	Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 717-720.	2.4	7

#	ARTICLE	IF	CITATIONS
37	High interfollicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma. Hematological Oncology, 2022, 40, 541-553.	1.7	6
38	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 200-200.	1.4	5
39	FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. Hematological Oncology, 2018, 36, 299-306.	1.7	4
40	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. Blood, 2018, 132, 1691-1691.	1.4	4
41	Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Lymphoma. Blood, 2020, 136, 16-17.	1.4	4
42	Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience.. Blood, 2012, 120, 2733-2733.	1.4	4
43	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 5310-5310.	1.4	3
44	Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients. Blood, 2015, 126, 3989-3989.	1.4	3
45	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. Blood, 2012, 120, 1553-1553.	1.4	2
46	Skip pattern approach toward the early access of innovative anticancer drugs. ESMO Open, 2021, 6, 100227.	4.5	1
47	Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy. Blood, 2016, 128, 4141-4141.	1.4	1
48	Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality. Blood, 2018, 132, 2867-2867.	1.4	1
49	DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPESED AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA. Hematological Oncology, 2019, 37, 429-430.	1.7	0
50	Clinical Relevance of Vascular Endothelial Growth Factor In Myelodysplastic Syndromes. Blood, 2010, 116, 4030-4030.	1.4	0
51	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. Blood, 2011, 118, 2847-2847.	1.4	0
52	Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience. Blood, 2012, 120, 4598-4598.	1.4	0
53	Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas. Blood, 2015, 126, 4503-4503.	1.4	0
54	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 4161-4161.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 3007-3007.	1.4	0
56	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. Blood, 2018, 132, 196-196.	1.4	0
57	Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity. Blood, 2020, 136, 34-34.	1.4	0